A Novel Genetic Mechanism of Caplacizumab Resistance in iTTP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Mari Thomas et al., adding:
“Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (iTTP) Associated with VWF A1 Domain Missense Variant
This landmark first report describes caplacizumab resistance in an iTTP patient caused by a VWF A1 domain missense variant (P1266L) that impairs drug binding, revealing a novel genetic mechanism of treatment failure beyond premature therapy discontinuation.”
Title: Caplacizumab resistance in immune thrombotic thrombocytopenic purpura is associated with a von Willebrand factor A1 domain missense variant
Authors: Mari Thomas, Imogen Buckle, Adela Constantinescu-Bercu, Rens De Groot, Sabina McCann, Marie Scully
Read the Full Article on JTH
Other articles about Journal of Thrombosis and Haemostasis
-
Jul 15, 2026, 14:27Factor XIII and the Future of Anticoagulation in VTE
-
Jul 15, 2026, 14:26Matthew D. Neal: From Platelet Biology to Patient Impact at ISTH 2026
-
Jul 15, 2026, 14:15Sarah Richardson: Today, I Ask You to Stand with the Bleeding Disorders Community
-
Jul 15, 2026, 14:03Anna Randi: Imperial College London’s Vascular Haemostasis and Thrombosis Team Shines at ISTH 2026
-
Jul 15, 2026, 13:53Akhil Antony Konkoth: Galectin-9 Emerges as a Key Mediator of Venous Thromboinflammation
-
Jul 15, 2026, 13:48Sabine Eichinger: New Insights into Recurrence Risk After Provoked VTE at ISTH 2026
-
Jul 15, 2026, 13:44Shirley D’Sa: Vitamin B6 Offers a New Clue in the POEMS Syndrome Puzzle
-
Jul 15, 2026, 13:43Katarina Miljević: New Insights into Recombinant tPA and FXI Inhibition at ISTH 2026
-
Jul 15, 2026, 13:31Sandrine Meunier: ISTH 2026 Highlights Consensus on Pediatric Hemostatic Assessment